QUALITY OF LIFE AND ABILITY TO WORK OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH THYROSINE KINASE INHIBITORS
Author(s): ,
Benlazar Sidi Mohamed El Amine
Affiliations:
Hematology department,Universitary hospital of Sidi Bel Abbes,Sidi Bel Abbes,Algeria
,
Hadjeb Asma
Affiliations:
Hematology department,Universitary hospital of Sidi Bel Abbes,Sidi Bel Abbes,Algeria
,
Zouaoui Zahia
Affiliations:
Hematology department,Universitary hospital of Sidi Bel Abbes,Sidi Bel Abbes,Algeria
,
Mesli Naima
Affiliations:
Hematology department,Universitary hospital of Tlemcen,Tlemcen,Algeria
Mehalhal Nemra
Affiliations:
Hematology department,Hospital of Mascara,Mascara,Algeria
EHA Library. BENLAZAR S. May 18, 2017; 181248; E1472
Prof. S.M.Amine BENLAZAR
Prof. S.M.Amine BENLAZAR
Contributions
Abstract

Abstract: E1472

Type: Eposter Presentation

Background
Thyrosine kinase inhibitors (TKIs) are now standard treatment for chronic myelogenous leukemia (CML), but little is known about quality of life (QoL) of the patients.

Aims

The purpose of this study is to evaluate QoL of CML patients receiving TKIs, a disease requiring strict daily compliance with taking these drugs orally, as well as regular clinical and biological controls.

Methods

The study included patients with CML followed in three hospitals in west Algeria between 2004 and 2016. The measure of QoL was performed by the tool of functional assessment of chronic illness therapy (Functional Assessment of Chronic Illness Therapy, FACIT) for leukemia.
We have established QoL scores given by the questionnaire, FACIT, consisting of three levels: TOI for leukemia trial outcome index, FACT-G for general score, and FACT-LEU for the total score of leukemia. Specific areas of the questionnaire were associated with QoL of patients such as fatigue and ability to work. The correlation between these data and QoL scores was assessed using Spearman's test. The test is significant if p <0.05.

Results

67 patients with CML have agreed to answer to the questionnaire of QoL, medications in use, and their side effects. The mean QoL of the patients was 93.7 (out of 124 total points) for the TOI, 77,2 (out of 108) for the FACT-G, and 128.9 (out of 176) for the FACT-LEU.
Patients who presented with TKIs side effects had a low score of QoL (p = 0.0006), especially when these effects are severe (p = 0.003). Stopping TKIs medication was noted in 41.3% of patients with severe side effects. Severe fatigue was observed in 14 (22.9%) patients, having low QoL scores in all scales (p <0.0001). 44 (65.8%) patients were able to work with higher QoL scores in the three FACIT scales (p <0.0001, Spearman correlation).

Conclusion

QoL is an important aspect in the management of CML, its assessment is necessary and must be regular. The ability to work and fatigue are important components of QoL of patients receiving TKIs and should be specifically taken into account during the treatment. Adverse effects of TKIs can interfere with QoL of patients and can lead to discontinuation of CML therapy.

Session topic: 35. Quality of life, palliative care, ethics and health economics

Keyword(s): Quality of Life, Fatigue, Chronic myeloid leukemia

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies